Investigation of Asprosin a Novel Adipokine in Periodontitis

NCT05449821 | Completed

• 1 other identifier: MIC2
• Study Type: observational
• Target: 65
• Locations: 1 country
• Sites: 1

Brief Summary

Asprosin, a recently discovered glucogenic adipokine, is mainly synthesized by white adipose tissue and released during fasting. Appetite, glucose metabolism, insulin resistance, cell apoptosis, etc. asprosin is associated with diseases such as diabetes, obesity, polycystic ovary syndrome, and cardiovascular diseases. Periodontal tissue may act as a source of endocrine-like inflammatory mediators (such as TNF-α, IL-6 and IL-1) that are important in periodontal inflammation and can affect glucose and lipid metabolism. Production of TNF-α and IL-6 in adipose tissues strengthens the relationship between obesity, T2DM and periodontitis.we postulated that asprosin may be candidate for explaining the triangular relationship among obesity, T2DM, and periodontal disease.

Conditions

Periodontitis; Obesity; Diabetes Mellitus

Outcome Measures

Primary Outcomes (1)

• Asprosin Levels

  Determination of asprosin levels by making biochemical analyzes from serum and saliva samples obtained

  two weeks

Study Arms (2)

Periodontitis group

35 subjects had periodontitis. Periodontitis will be staged by including patients with a periodontal pocket (PD) measurement of 4 mm and above, accompanied by attachment loss and radiographic bone loss.

Diagnostic Test: Serum and salivary samples will be collected. Asprosin levels will be determined by biochemical analysis

Healthy group

30 subjects had healthy periodontal tissue.Healthy controls included volunteers with clinically healthy gingiva on an intact periodontium who had BOP \< 10% and PD ≤ 3 mm, no sites with attachment loss, no radiographic sign of alveolar bone destruction, and no history of periodontitis.

Diagnostic Test: Serum and salivary samples will be collected. Asprosin levels will be determined by biochemical analysis

Interventions

Serum and salivary samples will be collected. Asprosin levels will be determined by biochemical analysis DIAGNOSTIC_TEST

Serum and saliva samples will be collected from both groups for biochemical analysis.

Healthy group; Periodontitis group

Eligibility Criteria

• Age: 18 Years - 60 Years
• Sex: all
• Age Groups: Adult (18-64)
• Sampling Method: Probability Sample

Study Population

All systemically healthy individuals between the ages of 18-60, who applied to the Atatürk University Faculty of Dentistry for periodontal examination, will be evaluated in the study. Patients who consent to participate in the study on a randomized basis and comply with the inclusion criteria will be divided into periodontitis and healthy groups after the periodontal examination. Body mass index will also be evaluated

You may qualify if:

• All individuals were generally healthy,
• non-smoking

You may not qualify if:

• Pregnant or breastfeeding women
• None had undergone periodontal therapy and/or antibiotic therapy in the past 6 months.
• None has a contagious disease such as HIV or AIDS

Sponsors & Collaborators

• Ataturk University: lead

Study Sites (1)

Atatürk University Faculty of Dentistry

Erzurum, 25240, Turkey (Türkiye)

Location

Related Publications (2)

• Romere C, Duerrschmid C, Bournat J, Constable P, Jain M, Xia F, Saha PK, Del Solar M, Zhu B, York B, Sarkar P, Rendon DA, Gaber MW, LeMaire SA, Coselli JS, Milewicz DM, Sutton VR, Butte NF, Moore DD, Chopra AR. Asprosin, a Fasting-Induced Glucogenic Protein Hormone. Cell. 2016 Apr 21;165(3):566-79. doi: 10.1016/j.cell.2016.02.063. Epub 2016 Apr 14.

  PMID: 27087445 BACKGROUND

• Yuan M, Li W, Zhu Y, Yu B, Wu J. Asprosin: A Novel Player in Metabolic Diseases. Front Endocrinol (Lausanne). 2020 Feb 19;11:64. doi: 10.3389/fendo.2020.00064. eCollection 2020.

  PMID: 32153505 BACKGROUND

Biospecimen

Retention: SAMPLES WITHOUT DNA

saliva and plasma samples

MeSH Terms

Conditions

Periodontitis; Obesity; Diabetes Mellitus

Condition Hierarchy (Ancestors)

Periodontal Diseases; Mouth Diseases; Stomatognathic Diseases; Overweight; Overnutrition; Nutrition Disorders; Nutritional and Metabolic Diseases; Body Weight; Signs and Symptoms; Pathological Conditions, Signs and Symptoms; Glucose Metabolism Disorders; Metabolic Diseases; Endocrine System Diseases

Study Officials

• Didem Özkal Eminoğlu, Asist. Prof.

  Atatürk University, Faculty of Dentistry

  STUDY CHAIR

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Assistant Professor

Study Record Dates

• First Submitted: July 5, 2022
• First Posted: July 8, 2022
• Study Start: January 1, 2022
• Primary Completion: November 1, 2022
• Study Completion: December 1, 2022
• Last Updated: February 1, 2023

Record last verified: 2023-01

Locations

TU (1)